Zeng H, Xu C, Fan J, et al. - On March 4, 2020, the National Health Commission of the People’s Republic of China released the seventh edition of the New Coronavirus Pneumonia Prevention and Control Protocol for the novel coronavirus disease 2019 (COVID-19) and added serological diagnostic criteria. In this work, these new criteria were applied to 6 pregnant women with confirmed COVID-19 and their infants at Zhongnan Hospital of Wuhan University from February 16 to March 6, 2020. Collection of blood samples from the mothers was done at delivery and of neonatal blood and throat swab samples was done at birth. Neonatal serum and throat swabs were assessed via conducting quantitative RT-PCR for SARS-CoV-2 nucleic acid (RT-PCR Kit, BioGerm). Neonatal serum was tested for inflammatory cytokines (CBA Human Th1/Th2 Cytokine Kit II, BD Biosciences). IgG and IgM antibodies were tested in maternal and neonatal sera samples. None of the serum or throat swab of the newborns displayed SARS-CoV-19 using RT-PCR. However, neonatal blood sera samples displayed virus-specific antibodies. Five infants had elevated IgG concentrations. Researchers suggest passive transfer of IgG across the placenta from mother to fetus beginning at the end of the second trimester and reaching high levels at the time of birth. However, because of the larger macromolecular structure, mother to fetus transfer of IgM, which was detected in 2 infants, do not occur usually. In a study of mothers with SARS, abnormal weights and pathology were observed in the placentas of 2 women who were convalescing from SARS-CoV infection in the third trimester of pregnancy. Alternatively, the infant could have produced IgM if the virus crossed the placenta.